Conserved polypeptides of Plasmodium falciparum as malaria vaccine candidates? 1991

S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
Department of Microbiology, School of Health, Universidad del Valle, Cali, Colombia.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000953 Antigens, Protozoan Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered. Protozoan Antigens
D016052 Protozoan Vaccines Suspensions of attenuated or killed protozoa administered for the prevention or treatment of infectious protozoan disease. Vaccines, Protozoan

Related Publications

S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
February 1991, Behring Institute Mitteilungen,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
October 2014, Cellular and molecular life sciences : CMLS,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
March 1986, Papua and New Guinea medical journal,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
August 2021, Scientific reports,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
January 2024, Biomolecules,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
March 2015, Trends in parasitology,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
October 2017, 3 Biotech,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
September 2008, Clinical and vaccine immunology : CVI,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
September 2021, Vaccines,
S Herrera, and M A Herrera, and C Clavijo, and A Corredor, and U Certa
August 2009, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!